Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Bolt Biotherapeutics (BOLT) EBIT Margin (2020 - 2025)

Historic EBIT Margin for Bolt Biotherapeutics (BOLT) over the last 6 years, with Q3 2025 value amounting to 355.14%.

  • Bolt Biotherapeutics' EBIT Margin rose 10859600.0% to 355.14% in Q3 2025 from the same period last year, while for Sep 2025 it was 884.39%, marking a year-over-year decrease of 1082600.0%. This contributed to the annual value of 949.91% for FY2024, which is 175400.0% up from last year.
  • Per Bolt Biotherapeutics' latest filing, its EBIT Margin stood at 355.14% for Q3 2025, which was up 10859600.0% from 510.53% recorded in Q2 2025.
  • Bolt Biotherapeutics' 5-year EBIT Margin high stood at 324.08% for Q1 2024, and its period low was 5329.72% during Q4 2021.
  • Its 5-year average for EBIT Margin is 1565.75%, with a median of 1221.0% in 2022.
  • Its EBIT Margin has fluctuated over the past 5 years, first surged by 38385800bps in 2022, then tumbled by -7218400bps in 2024.
  • Quarter analysis of 5 years shows Bolt Biotherapeutics' EBIT Margin stood at 5329.72% in 2021, then surged by 72bps to 1491.14% in 2022, then skyrocketed by 37bps to 946.19% in 2023, then tumbled by -52bps to 1441.1% in 2024, then soared by 75bps to 355.14% in 2025.
  • Its last three reported values are 355.14% in Q3 2025, 510.53% for Q2 2025, and 991.41% during Q1 2025.